ClinicalTrials.gg
Active, not recruitingNCT07541001China Phase IIUpdated Apr 23, 2026

PRL3-Zumab in Patients With Advanced Solid Tumors

A Phase 2 interventional study of PRL3-ZUMAB in Advanced Malignant Solid Tumor, sponsored by Intra-IMMUSG Pte Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Intra-IMMUSG Pte Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.
  • Registered 4 years 7 months after the study started (first participant enrolled Aug 2021, registered Apr 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors. PRL3-zumab will be administered via intravenous (IV) infusion until discontinuation criteria are met (e.g., disease progression per RECIST v1.1/iRECIST, intolerable toxicity, or withdrawal of consent).

Study Periods and Duration

The study is divided into the following phases:

  • Screening Period: Day -21 to Day -1; all assessments must be completed prior to the first dose.
  • Treatment Period: One cycle is defined as 4 weeks, consisting of two infusions administered 2 weeks apart.
  • End-of-Treatment (EOT) Visit: To be conducted within 14 days of the last dose or treatment discontinuation.
  • Safety Follow-Up: A visit scheduled 30 days after the last dose.
  • Survival Follow-Up: Conducted every 3 months post-discontinuation via telephone or other appropriate methods until the data cutoff date.

Assessments

  • Safety \& QoL: Safety assessments (including laboratory tests) will be performed prior to each infusion. Quality of Life (QoL) will be assessed at screening and every 8 weeks during treatment.
  • Tumor Imaging: Assessments will be performed at baseline and every 8 weeks following the initiation of study treatment, according to RECIST v1.1 and iRECIST.
  • Immunogenicity: Assessments will be performed pre-dose on Cycle 1 Day 1, and prior to infusions in Cycles 2, 4, and 6. For patients remaining on treatment, assessments will continue every 3 cycles thereafter.

Pharmacokinetic (PK) profiles will be evaluated in two distinct subgroups of 10 patients each. For the intensive PK sampling subgroup, assessments are concentrated in the first three cycles: Cycle 1 monitoring includes Day 1 (pre-dose, end of infusion, 2, and 6 hours post-infusion), Day 2 (24 hours), Day 6 (120 hours), Day 10 (216 hours), and Day 15 (pre-dose). Following pre-dose samples on Cycle 2 (Days 1 and 15) and Cycle 3 (Day 1), a second intensive window occurs on Cycle 3 Day 15 (pre-dose, end of infusion, 2, and 6 hours post-infusion) and continues through Days 16, 20, and 24. Subsequent samples are taken pre-dose on Day 1 of Cycles 4, 5, and 6, concluding at the EOT visit. In contrast, the sparse PK sampling subgroup will undergo limited assessments at Cycle 1 Day 1 (pre-dose and end of infusion), Cycle 1 Day 15 (pre-dose), and the first day of Cycles 2 and 3 (pre-dose and end of infusion), with a final sample collected at the EOT visit.

Read the detailed description

Study Assessments

Efficacy:

Efficacy will be evaluated by the investigator using RECIST v1.1 and iRECIST criteria. Tumor evaluations, including contrast-enhanced computed tomography (CT) scans, will be performed at baseline (within 14 days prior to Cycle 1 Day 1) and every 56 days thereafter. Magnetic resonance imaging (MRI) may be used if a patient is ineligible for CT scans; however, the same imaging modality must be used consistently throughout the study.

Safety:

Patient safety will be assessed on an ongoing basis during each cycle. Evaluations include physical examinations, vital signs (systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature), and clinical laboratory tests (hematology, clinical chemistry, and coagulation). Adverse events (AEs) will be graded according to CTCAE v5.0.

Pharmacokinetics (PK):

Blood samples for PK analysis will be collected as follows:

  • Intensive Sampling Group (N=10): C1D1 (pre-dose, EOI, 2h, and 6h post-infusion), C1D2 (24h), C1D6 (120h), C1D10 (216h), C1D15 (pre-dose); C2D1 and C2D15 (pre-dose); C3D1 (pre-dose), C3D15 (pre-dose, EOI, 2h, and 6h post-infusion), C3D16 (24h), C3D20 (120h), C3D24 (216h); C4D1, C5D1, C6D1 (pre-dose), and at End of Treatment (EOT).
  • Sparse Sampling Group: C1D1 (pre-dose, EOI), C1D15 (pre-dose); C2D1 and C3D1 (pre-dose and EOI), and at EOT.

Immunogenicity \& Quality of Life (QoL) Anti-drug antibody (ADA) samples will be collected prior to infusion on C1D1 and Cycles 2, 4, and 6. Thereafter, samples will be collected every three months. Neutralizing antibody assessments will be performed for any patient testing positive for ADA.

Quality of Life (QoL) will be measured using EQ-5D and EORTC-QLQ-C30 questionnaires at screening and every 2 cycles (8 weeks ± 2 days for C1-C4; 8 weeks ± 7 days thereafter).

Study Duration and Periods

  • Cycle Period: One cycle is 28 days (two infusions administered 2 weeks apart).
  • Treatment Period: Treatment continues until disease progression (per RECIST 1.1/iRECIST or clinical criteria), intolerable toxicity, or withdrawal of consent.
  • Follow-up Period: Includes a Safety Follow-up (30 ± 7 days after the last dose or prior to new therapy) and a Survival Follow-up (every 3 months via telephone until the data cutoff date, which is 24 weeks after the last subject's enrollment).

Statistical Considerations

Sample Size and Populations:

This is an exploratory trial; thus, the sample size is not based on formal hypothesis testing. A total of 50 subjects will be enrolled, with approximately 30 evaluable subjects expected for PFS and TTP assessments. Patients receiving fewer than 4 doses or lacking at least one post-baseline assessment will be replaced.

Analysis Sets:

  • Safety Set (SS): All patients receiving dose of study treatment.
  • Full Analysis Set (FAS): All patients receiving dose with measurable lesions at baseline.
  • Per Protocol Set (PPS): A subset of the FAS excluding those with major protocol deviations.
  • Evaluable Population Set (EPS): FAS patients with evaluable post-baseline tumor assessment.
  • PK/ADA Sets: Patients with dose and valid post-baseline PK/ADA measurements.

Statistical Methods:

Analyses will be performed using SAS® v9.4 or later. Categorical variables will be summarized by frequency/percentage, and continuous variables by descriptive statistics (mean, SD, median, range).

  • Efficacy: The primary endpoints, Progression-Free Survival (PFS) and Time to Progression (TTP), will be analyzed using Kaplan-Meier methods. Secondary endpoints (ORR, CBR) will include 95% confidence intervals (Clopper-Pearson).
  • Pharmacokinetics: PK parameters will be summarized descriptively. A population PK model will be developed.
  • Safety: TEAEs and treatment-related AEs (TRAEs) will be summarized by System Organ Class (SOC) and Preferred Term (PT). Laboratory and vital sign changes from baseline will be summarized descriptively.
02

Conditions studied

  • Advanced Malignant Solid Tumor

Keywords

  • PRL3-zumab
  • Phase II China Trial
03

In context

Lead sponsor

Intra-IMMUSG Pte Ltd is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women aged 18 or older with unresectable or solid tumors
  2. Patients with locally advanced or metastatic solid tumors who have failed standard therapy or for whom no standard therapy is available. Treatment failure is defined as disease progression during or after systemic antitumor therapy (including but not limited to chemotherapy, radiotherapy, biologic therapy, immunotherapy, and endocrine therapy), or intolerance to treatment-related toxicities. Disease progression must be documented by radiographic evidence or clinical evidence. For patients who have received or neoadjuvant therapy (radiotherapy or chemoradiotherapy), disease progression occurring during treatment or after completion of such therapy will be considered treatment failure.
  3. Willing to provide written for the study.
  4. Histopathological diagnosis and metastatic status cancer at study entry.
  5. Must have received no more than 3 for metastatic disease.
  6. of more than 6 months
  7. (ECOG) performance status (PS) score of 0 or 1.
  8. Patient should have recovered from toxicity of prior treatment regimen to Grade 1 level except for alopecia or peripheral neuropathy or fatigue as defined by (CTCAE version 5.
  9. Women of (WOCBP) must have a negative serum pregnancy test at study entry and must follow highly effective

    1. WOCBP must be willing to use highly effective methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide,) for the duration of the study and 90 days thereafter.
    2. Male participants should take precaution to avoid pregnancy in sexual partner during the study and 90 days thereafter.
  10. Adequate organ and hematological function as evidenced by the following laboratory studies within 10 days of treatment:

    • ≥ 1.0 x 109/L to 8.0 × 10⁹/L.
    • Lymphocyte count ≥ 0.9 × 10⁹/L
    • count ≥ 75 x 109/L.
    • ≥ 9 g/dL.
    • and activated partial thromboplastin time ≤ 1.5 x (ULN) per institutional laboratory normal range.
    • Total ≤ 1.5x ULN.
    • and alanine aminotransferase ≤ 2.5 x upper limit of normal (ULN) (≤ 5 x ULN in the presence of liver metastases).
    • For patients with hepatocellular carcinoma (HCC) score of ≤ B7.
    • Creatinine \< 1.5x ULN. (according to Cockcroft-Gault Equation or by 24-hour urine collection) of > 60 mL/min at study entry.
  11. According to 1.1 and , patients mush have at least one that meets the following criteria: Accurately measureable at baseline. Longest diameter ≥10mm at baseline (for lymph nodes, short axis ≥ 15mm). Measurable by a reproducible imaging method such as computed tomography (CT) or magnetic resonance imaging (MRI). If only one measurable lesion is present, it must not have been previously treated with local therapy such as radiotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Patient has known untreated or symptomatic central nervous system .
  2. Female patient is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for 150 days (for pregnancy or conception) or 30 days (for breastfeeding) after the last dose of study treatment.
  3. Patient with any of the following virologic findings:

    • Positive surface antigen (HBsAg) and positive HBV DNA
    • Positive anti- antibody and positive
    • Positive HIV antibody
  4. Patients with active disease requiring systemic treatment, or with a history of autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis), or patients at high risk (e.g., prior organ transplantation requiring therapy).
  5. Patient is receiving systemic (only if higher than 10 mg or equivalent of prednisolone daily) or other immunosuppressive treatment for autoimmune disease or any other medical condition.
  6. Patient has experienced a severe reaction to another monoclonal antibody.
  7. Patient has received treatment with any systemic anti-cancer therapies within 3 weeks prior to starting study treatment.
  8. Patient has undergone radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study treatment.
  9. Patient has received > 3 lines of prior systemic chemotherapy for metastatic disease ( or neoadjuvant chemotherapy treatment completed at least 1-year prior is not to be included in this).
  10. Patient is unable to provide .
  11. Patient has a history of another active cancer (which requires treatment and not considered cured by the investigator) within the last 2 years.
  12. Patient has received a prior stem cell or bone marrow transplant.
  13. Patient has received a within 12 weeks of the first dose of PRL3-zumab. (Seasonal influenza vaccines that do not contain live virus are permitted).
  14. Patient is currently participating in a treatment study or has participated in a study of an agent within 4 weeks prior to the anticipated first dose of study treatment in this study.
  15. Patients with spinal cord compression caused by tumor, unless the condition has been treated and clinically stable for more than 1 month.
  16. Patients with any unstable medical condition or any other disease that may compromise their safety or compliance with the study, including any severe or uncontrolled systemic disease such as uncontrolled hypertension, uncontrolled diabetes mellitus, or active bleeding.
  17. Patients with alcohol dependence or a history of drug abuse or substance abuse within 1 year prior to study entry.
  18. Patients with any other severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality, that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results.
  19. Patients who, in the investigator's judgment, are not suitable for participation in this study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    PRL3-zumab treated arm

    6mg/kg of PRL3-zumab will be administered

    Biological: PRL3-ZUMAB

Interventions

  • BiologicalPRL3-ZUMAB

    PRL3-zumab is an humanized anti PRL3 antibody targeted to PRL3 antigen in cancer cells

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    PFS is defined as the time from the initiation of study treatment to the date of disease progression as per RECIST v1.1 and iRECIST criteria.

    Time frame: Time Frame: From the date of first dose of study drug until first documented disease progression or date of death from any cause, whichever comes first, assessed up to 12 months.

  2. Time to Progression (TTP)

    TTP is defined as the time from the the initiation of study treatment to the date of disease progression as per RECIST v1.1 and iRECIST criteria which does not include deaths.

    Time frame: From the date of first dose of study drug until first documented disease progression, assessed up to 12 months.

Secondary outcomes

  1. Clinical benefit rate (CBR)

    CBR is defined as the percentage of patients with CR, PR, or stable disease (SD) as per RECIST v1.1 and iRECIST criteria based on Investigator's assessment.

    Time frame: Time Frame: From date of first dose of study drug until first documented disease progression or date of death, whichever comes first, assessed at every 8 weeks up to 48 weeks.

  2. Objective Response Rate (ORR)

    CBR is defined as the percentage of patients with CR or PR as per RECIST v1.1 and iRECIST criteria based on Investigator's assessment.

    Time frame: Time Frame: From date of first dose of study drug until first documented disease progression or date of death, whichever comes first, assessed at every 8 weeks up to 48 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Requests for IPD can be submitted by email to min.thura@intra-immusg.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Jun 2026, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 21, 2026
StartActual
Aug 30, 2021
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07541001
Lead sponsor
Intra-IMMUSG Pte Ltd
Collaborators
The First Affiliated Hospital of Xiamen University, Shanghai Chest Hospital, Hubei Cancer Hospital, Henan Cancer Hospital, Beijing Friendship Hospital, Fujian Provincial Hospital, Hangzhou Cancer Hospital
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Aug 30, 2021
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 23, 2026

Study contacts

Prof Qi Zeng
study director · Intra-IMMUSG Pte Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PRL-3 Monoclonal Antibody PRL3-zumab

Start the discussion